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Background: Idiopathic pulmonary fibrosis (IPF) is a life-limiting lung disease with considerable impact on patients
and carers as the disease progresses. Currently few treatments are available. We aimed to evaluate the clinical and
cost-effectiveness of available treatments for IPF.
Methods: Systematic reviews of clinical effectiveness, quality of life and cost effectiveness were undertaken. Eleven
bibliographic databases were searched from inception to July 2013 and studies were assessed for eligibility against
a set of pre-defined criteria. Two reviewers screened references, extracted data from included studies and appraised
their quality. An advisory group was consulted about the choice of interventions. A narrative review was undertaken
and where feasible fixed effect and random effects meta-analysis were undertaken including a network
meta-analysis (NMA).
A decision-analytic Markov model was developed to estimate cost-effectiveness of pharmacological treatments for
IPF. Following best practice recommendations, the model perspective was of the national health service and
personal social services, a discount rate of 3.5% for costs and health benefits was applied and outcomes were
expressed as cost per quality adjusted life-year gained. Parameter values were obtained from the NMA and
systematic reviews. Sensitivity analyses were undertaken.
Results: Fourteen studies were included in the review of clinical effectiveness, of which one evaluated azathioprine,
three N-acetylcysteine [NAC] (alone or in combination), four pirfenidone, one nintedanib, one sildenafil, one
thalidomide, two pulmonary rehabilitation, and one a disease management programme. Study quality was generally
good. Evidence suggests that some effective treatments are available. In NMA only nintedanib and pirfenidone show
statistically significant improvements. The model results show increased survival for five pharmacological treatments
(NAC triple therapy, inhaled NAC, nintedanib, pirfenidone, and sildenafil) compared with best supportive care, at
increased cost. Only inhaled NAC was cost-effective at current willingness to pay thresholds but it may not be clinically
effective.
Conclusions: Few interventions have any statistically significant effect and the cost-effectiveness of treatments is
uncertain. A lack of studies on palliative care approaches was identified and there is a need for further research into
pulmonary rehabilitation and thalidomide in particular. A well conducted RCT on inhaled NAC therapy should also be
considered.
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Idiopathic pulmonary fibrosis (IPF) is a debilitating
respiratory condition for which there is no cure. IPF is
characterised by aberrant wound healing in which exces-
sive (and perhaps abnormal) extracellular matrix is de-
posited in the lung thereby distorting the architecture
and disrupting function. This lung injury and scarring
eventually leads to a decline in lung function which cul-
minates in respiratory failure [1]. Shortness of breath on
exercise and a chronic dry cough are the prominent
symptoms [2]. IPF is known to affect males more than
females and in particular affects people over 60 years of
age. The prevalence of IPF is increasing, although the
cause of this increase is uncertain, [3,4] and with a poor
prognosis (estimated mean survival of between 2–5
years) IPF has become an area of focus with recent UK
national guidelines on the diagnosis and management of
IPF published, [5] and international consensus guidelines
[6] due to be updated in 2014.
IPF is a difficult condition to manage, particularly in
the latter stages. Early and accurate diagnosis is import-
ant to maximise the potential for a better outcome but
there is an unmet need with few recommended treat-
ments [5]. In the UK all patients should be given best
supportive care (BSC) from the point of diagnosis, which
includes information and support, symptom relief, man-
agement of co-morbidities, withdrawal of ineffective ther-
apies and end-of-life care. In addition individuals should
be assessed for pulmonary rehabilitation if appropriate
and have a clinical nurse specialist available to them [5].
For those without contraindications lung transplantation
should be considered as this is the only treatment shown
to improve survival [7]. However, with donor organs being
in short supply there is a need for alternative treatments
that aim to modify the disease and prolong survival. Few
treatments are available to the clinician and patient cur-
rently, and the evidence for the effectiveness of such treat-
ments is unclear. We aimed to evaluate the current state
of the clinical and cost-effectiveness of treatments for
people with IPF through three systematic reviews, a net-
work meta-analysis (NMA) and economic modelling.
Methods
The a priori methods for this evidence synthesis are
described in the research protocol which is registered with
PROSPERO (reference: 42012002116). Search strategies
were developed and applied to 11 electronic bibliographic
databases (including the Cochrane library, MEDLINE and
EMBASE) from inception to July 2013 with no language re-
strictions. Bibliographies of retrieved papers were screened
and experts contacted to identify additional studies. Sys-
tematic reviews were undertaken of clinical effectiveness
(including only randomised controlled trials [RCTs] and
controlled clinical trials [CCTs]), economic evaluations andhealth related quality of life (HRQoL) studies. Eligible par-
ticipants were those with a diagnosis of IPF and includable
interventions were as deemed relevant by a clinical and
patient advisory group. Best supportive care, placebo or any
of the interventions were eligible as comparators and out-
comes of relevance included measures of survival, measures
of symptoms (breathlessness, cough), HRQoL, lung func-
tion, exercise performance, adverse events and measures of
costs and cost-effectiveness. Studies reporting HRQoL in
people with IPF were eligible for inclusion if they used
either generic preference-based measures or the St Georges
Respiratory Questionnaire (SGRQ) which is a disease spe-
cific instrument used in IPF. Other disease specific instru-
ments were not eligible for inclusion as there are currently
no methods to map results of these to utility measures
required for economic evaluation.
Titles and abstracts were screened for potential eligi-
bility by two reviewers using a pre-defined inclusion
criteria, retrieved articles were assessed for eligibility, data
were extracted and methodological quality assessed by
one reviewer and checked by a second. Study quality was
assessed using recognised methods [8-10]. For the review
of clinical effectiveness we developed a check-list to assess
the methodological quality of the studies based on the
criteria recommended by the Centre for Reviews and Dis-
semination, [8] (Quality assessment/risk of bias section)
and summarised the risk of bias (as per Cochrane collab-
oration recommendations [11]) within each study accord-
ing to the risk of selection bias. We developed a check-list
to assess the methodological quality of the cost effective-
ness studies based on the check-list of Drummond and
colleagues [9] and recommendations by Phillips and col-
leagues [10]. Data items extracted included study details
(design, follow-up, funding), participant details (numbers,
eligibility, characteristics), intervention details (including
dose and duration of treatment), outcomes reported and
results. Narrative syntheses were undertaken and in the
review of clinical effectiveness meta-analysis was per-
formed where appropriate with heterogeneity assessed.
FVC was measured on two continuous scales and these
were meta-analysed using the standardised mean differ-
ence (SMD). A NMA focusing on pharmacological treat-
ments for IPF and assessing forced vital capacity (FVC)
endpoints was undertaken [12].The NMA focused on
FVC as it is correlated with disease progression [6] and
was therefore relevant to the economic model. For FVC
endpoints the NMA used the SMD in a Bayesian frame-
work using code adapted from published sources [13].
Vague normal priors were used for the treatment effects
and a vague uniform prior for the random effect standard
deviation. Model code is provided in the Additional file 1.
Fixed and random effects models were applied with best
model fit determined using the deviance information cri-
terion (DIC). The SMDs output from the NMA were then
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ease of interpretation within the context of an NMA [14].
Quality assessment/risk of bias
1. Was the method used to generate random
allocations adequate?
2. Was the allocation adequately concealed?
3. Were the groups similar at the outset of the study in
terms of prognostic factors
4. Was the care provider blinded?
5. Was the patient blinded?
6. Were outcome assessors blinded to the treatment
allocation?
7. i) Were there any unexpected imbalances in
drop-outs between groups? ii) If so, were they
explained or adjusted for?
8. Is there any evidence to suggest that the authors
measured more outcomes than they reported?
9. i) Did the analysis include an intention to treat
analysis? ii) If so, was this defined?
10. i) Did the analysis account for missing data? ii) If
so, were the methods appropriate?
A decision-analytic model was developed to compare
the cost-effectiveness of pharmacological interventions
in patients with initially unprogressed IPF. The model
perspective is that of the UK National Health Service
and Personal Social Services. The model structure was
informed by the available literature and expert opinion
on the clinical progression of the disease. It uses four
distinct health states: unprogressed IPF; progressed IPF;
lung-transplant; and dead. Health states except death are
associated with a HRQoL utility and a cost estimate.
Progression is defined by an absolute decline in FVC per
cent predicted of ≥10% from a baseline (recently-diag-
nosed) value, based on the included RCTs. Published
sources were used to inform the probability of a lung
transplant; survival after lung transplant; and all-cause
mortality by age. Acute exacerbations are not modelled
as separate health states but are associated with a cost
and utility decrement. Model cycle length is one month
and a lifetime horizon of 30 years was adopted to cap-
ture all clinically and economically important events. A
half-cycle correction is applied. Key assumptions are that
all patients are in in the unprogressed state initially;
those experiencing a ≥10% absolute decline in FVC%
predicted are considered to be in the progressed health
state; and treatment has a constant effect on relative rate
of FVC% decline, FVC% predicted was used as a proxy
for disease severity when assigning utilities to the health
states. In addition, where treatment costs for any indi-
vidual treatment were not available an assumed cost was
used and tested in threshold analysis.Treatment effects were obtained from the NMA.
Utility values from the systematic review of HRQoL are
applied to the modelled health states to estimate the
benefits measured as quality adjusted life years (QALYs).
Costs are included for treatments, treatment monitoring,
acute exacerbations, lung transplant and adverse events,
based on the UK health system. Future costs and bene-
fits are discounted at 3.5% per annum. The outcome is
reported as cost per QALY gained against the next best
alternative treatment using incremental cost effectiveness
ratios (ICERs). The model examines uncertainty in deter-
ministic and probabilistic sensitivity analyses. Model valid-
ation was undertaken by checking structure, calculations
and data inputs. In addition the advisory group reviewed
the structure and internal consistency was examined by
varying input values. Model results were compared with
trial outputs and other publications [15-17].Results
Clinical effectiveness
Searches identified 905 unique references and 64 of these
were retrieved after screening of titles and abstracts. Four-
teen studies (13 RCTs and 1 CCT) were included (Figure 1).
Four RCTs evaluated the use of pirfenidone, [15,18,19]
three the use of n-acetylcysteine (alone or in combin-
ation), [20-22] one azathioprine, [23] one nintedanib, [16]
one sildenafil, [24] one thalidomide, [25] one a pulmonary
rehabilitation programme, [26] and one a disease manage-
ment programme [27]. In addition one CCT of pulmonary
rehabilitation was included [28]. This study was published
in Polish and translation of key methods and results only
were undertaken due to resource and time constraints.
Therefore caution is recommended in interpreting our as-
sessment of this study. No studies of palliative care inter-
ventions were identified that met the inclusion criteria.
Study quality was generally good with a low risk of bias.
Ten studies were undertaken in populations that would
likely be classed as mild to moderate IPF [29]. The major-
ity of these studies had reasonable sample sizes and dur-
ation of follow was between nine months and 16 months.
Four studies were undertaken in populations that would
be classed as moderate to severe IPF. Three of these were
the non-pharmacological intervention studies, and one the
drug sildenafil. Sample sizes were generally smaller in the
non-pharmacological studies, and there was no long-term
follow up. Across all studies the mean ages of participants
ranged from approximately 54–69 years, the gender ratio
of males to females was generally 3:1, and the duration of
diagnosis tended to be between 1 and 3 years. In the ten
studies in mild-to-moderate IPF the baseline FVC ranged
between 65-90% and in the four studies in moderate-to-
severe IPF this ranged from 55-70%. The populations were
deemed to be reasonably similar to those seen in clinical
Identified on searching                                               
n = 1310




n =  905
Full papers inspected
n=64
Potentially eligible                                  
n = 47
Interventions sent to advisory 
group
Included n = 15 publications a
(14 trials)
n = 1 protocolb
Excluded n = 841
Excluded with reasons
n = 17
Excluded n = 31 
Figure 1 Flow chart for the identification of studies in the clinical
effectiveness review. a Two RCTs were reported in one publication;
two further trials each had two linked publications. b One trial was
published as a protocol only.
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details see Table 1.
Results for the clinical effectiveness of the five pharma-
cological interventions in patients with mild to moderate
IPF were mixed. In clinical practice azathioprine is only
used in restricted circumstances, in one RCT [23] azathio-
prine and prednisolone led to an improvement in survival
compared with placebo and prednisolone when an age
adjusted analysis was used. There was no effect on lung
function. This trial had an unclear risk of bias, a small
sample size, and it is uncertain whether all patients had a
diagnosis of IPF based on current recommendations.
Consequently, caution is recommended when interpreting
results. Nintedanib 300 mg/day was more favourable than
placebo on some FVC measures, acute exacerbations and
mortality, however, the primary outcome of annual rate of
decline in FVC was not statistically significant [16]. Treat-
ment with NAC was evaluated in three studies, [20-22] in
combination with azathioprine and prednisolone in two
(triple therapy) and in an inhaled format in one. Study re-
sults were mixed and establishing the stand-alone effect of
NAC is difficult due to the differences between the three
studies. There was no benefit from triple therapy on FVC
compared to placebo in one trial, however, there was abenefit on vital capacity (VC) when compared to azathio-
prine and prednisolone in another. The treatment effect of
inhaled NAC was not statistically different from that of a
control group (p = 0.05). The study using inhaled NAC had
an unclear risk of bias which should be considered when
interpreting results. Four RCTs [15,18,19] evaluated the use
of pirfenidone and meta-analysis shows that pirfenidone
appears to demonstrate a significant effect on FVC when
compared to placebo (SMD 0.24, 95% CI 0.06, 0.41, p =
0.008). This should be cautiously interpreted as the out-
comes pooled were different, the timing of assessment var-
ied (from 48 weeks to 72 weeks) and there was moderate
statistical heterogeneity (I2 = 45%). The effect of pirfenidone
on secondary outcomes was more uncertain. Thalidomide
was assessed in those with cough in a small crossover RCT
[25]. HRQoL outcomes related to cough were improved with
thalidomide compared to placebo. There is no evidence
relating to any subgroups in any of the published studies.
One study [24] assessed sildenafil for those with mod-
erate to severe IPF. No statistically significant benefit of
sildenafil was seen on the primary outcome, a 20%
improvement on the six minute walk test. Results on
secondary outcomes were mixed with some favourable
to sildenafil but others being not statistically significant.
Adverse events were generally mild to moderate and
reasonably well balanced between the treatments and
controls with the exception of thalidomide which led to a
greater proportion of people experiencing at least one
adverse event (77%) than the placebo treated participants
(22%) [25]. Severe adverse events appeared to be more com-
mon in one study in those treated with triple therapy [21].
Ten studies of pharmacological interventions were in-
cluded in NMA; the resulting evidence network is shown
in Figure 2. Thalidomide was excluded as the focus of
treatment is not on lung function. Inhaled NAC was con-
sidered separately from triple therapy owing to its different
method of administration. Both direct and indirect evi-
dence was used to assess the treatment effect compared to
placebo. Only the fixed effect results for nintedanib and
pirfenidone were statistically significant, odds ratios for
reducing the rate of decline in FVC compared to placebo
are shown in (Table 2). The random effects model did not
demonstrate a better fit than the fixed effect model and
there was no evidence of inconsistency within the evi-
dence network. A head-to-head comparison of nintedanib
versus pirfenidone suggested a trend favouring nintedanib,
but this was not statistically significant and should be cau-
tiously interpreted in the light of the various differences
between the studies (Table 2). Further trial evidence could
be used to test this further.
Three non-pharmacological intervention studies com-
pared a pulmonary rehabilitation programme or disease
management programme to control interventions in
moderate-to-severe IPF. Results from the two pulmonary
Table 1 Study characteristics of included interventions
Study and intervention
details




Raghu et al. 1991 [21] Mean Age: 56 years Primary outcomes: not stated
as primary or secondary:
measurable change in lung
function (FVC, DLCO, P[A-a]O2)
at 12 months; survival
Unclear risk
Country: USA M/F%: 55/45
Design: RCT Time since diagnosis: 2 years
Number of centres: 2 FVC: 67%
Funding: Grant from Virginia Mason ResearchCentre,
Seattle, USA
Length of follow-up: 12 months
Interventions:
1. Prednisone and placebo, n = 13
2. Prednisone and azathioprine, n = 14
Duration of treatment: 12 months
BIBF-1120
Richeldi et al. 2011 [22] Mean Age: 65 years Primary outcomes: annual rate of
decline in FVC
Low risk
Country: 25 countries including Italy, Mexico, M/F%: 75/25
Germany, USA, Korea, UK, France. Time since diagnosis: 1.2 Secondary outcomes: % predicted
FVC; DLCO; SpO2; TLC; 6MWT,
SGRQ, decrease in FVC of more
than 10% or more than 200 ml; SpO2
decrease of more than 4%; acute
exacerbations; survival; death from
a respiratory cause; adverse events
Design: RCT (dose finding phase II study) years
Number of centres: 92 FVC: 80%
Funding: supported by Boehringer Ingelheim
Interventions:
1. BIBF 1120 50 mg/day, n = 86
2. BIBF 1120 50 mg twice per day (100 mg/day), n = 86 Length of follow-up: 54 weeks
3. BIBF 1120 100 mg twice per day (200 mg/day), n = 86
4. BIBF 1120 150 mg twice per day (300 mg/day), n = 85
5. Placebo, n = 85
Duration of treatment: 52 weeks
N-Acetylcysteine (alone or in combination)
Demedts et al. 2005 [18] Mean Age: 63 years Primary outcomes: absolute changes
in VC and DLCO at 12 months
Low risk
Country: Belgium, France, Germany, Italy, Spain,
the Netherlands
M/F%: 72/28
Design: RCT Time since diagnosis:
1.6 years
Secondary outcomes: % predicted VC, %
predicted DLCO, alveolar volume
change and % predicted, CRP score,
dyspnoea score, maximum exercise
indexes, HRCT outcomes, SGRQ, adverse
events, withdrawals, and mortality
Number of centres: 36 FVC: 66%
Funding: sponsored by the Zambon group
Interventions:
1. N-acetylcysteine, prednisolone, azathioprine, n = 92
(80 analysed)
2. Placebo, prednisolone, azathioprine, n = 90 (75 analysed) Length of follow-up: 12 months
Duration of treatment: not stated, assume 12 months.
Raghu et al., (IPFCRN) 2012 [19] Mean Age: 68 years Primary outcomes: change in
FVC at 60 weeks
Low risk
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Table 1 Study characteristics of included interventions (Continued)
Country: USA M/F%: 75/25
Design: RCT (PANTHER study) Time since diagnosis: 1 year Secondary outcomes: rate of death,
time until death, frequency of acute
exacerbation, frequency of maintained
FVC response, time to disease progression,
clinical and physiological measures including:
DLCO, 6MWT, CPI, UCSD SBQ, SGRQ,
SF-36, EQ-5D. Adverse events.
Number of centres: 25 FVC: 71%
Funding: grants from the NHLBI; the Cowlin Family fund.
NAC and placebo donated by Zambon
Interventions:
1. N-acetylcysteine and placebo (data not presented
in article as ‘ongoing’ data collection), n = 81
2. N-acetylcysteine/prednisolone/azathioprine, n = 77 Length of follow-up: 60 weeks in the
planned analysis. The study was stopped
early. The mean follow-up was 32 weeks.3. Placebo, n = 78
Duration of treatment: up to 60 weeks
Homma et al. 2012 [20] Mean Age: 68 years Primary outcomes: absolute change
in FVC at 48 weeks
Unclear risk
Country: Japan M/F%: 76/24
Design: RCT Time since diagnosis:
3 years
Number of centres: 27 FVC: 89% Secondary outcomes: changes in lowest
aterial O2 saturation, 6MWT distance,
PFT parameters (VC, % predicted VC,
TLC, % predicted TLC, DLCO, predicted
DLCO), serum markers of pneumocyte
injury; disease progression as determined
by HRCT; subjective changes in symptoms
such as dyspnoea, adverse events.
Funding: grant from Ministry of Health, Labour and
Welfare
Interventions:
1. N-acetylcysteine inhaled, n = 51 (38 analysed)
2. Control, n = 49 (38 analysed) Duration of treatment:
48 weeks
Length of follow-up: 48 weeks
Pirfenidone
Noble et al., 2011 [15] Mean Age: 67 years Primary outcomes: change in per
cent predicted FVC
Low risk
Capacity study 006 M/F%: 72/28
Country: Australia, Belgium, Canada, France, Germany,
Ireland, Italy, Mexico, Poland, Spain, Switzerland, UK, USA
Time since diagnosis: ≤1
year: 59% Secondary outcomes: categorical FVC
(5-point scale), progression-free survival,
worsening IPF, dyspnoea, 6MWT distance,
worst peripheral oxygen saturation (SpO2)




Number of centres: 110 centres
Funding: InterMune
Interventions:
1. Pirfenidone 2403 mg/day, n = 171 Length of follow-up: 72 weeks from
the date the last patient was enrolled.
2. Placebo, n = 173
Duration of treatment: 72 weeks
Noble et al., 2011 [15] Mean Age: 66 years Primary outcomes: change in per cent
predicted FVC
Low risk
Capacity study 004 M/F%: 71/29
Country: Australia, Belgium, Canada, France, Germany, Ireland,
Italy, Mexico, Poland, Spain, Switzerland, UK, USA
Time since diagnosis: ≤1
year: 48% Secondary outcomes: categorical FVC
(5-point scale), progression-free survival,
worsening IPF, dyspnoea, 6MWT distance,
worst peripheral oxygen saturation (SpO2)




Number of centres: 110 centres
Funding: InterMune
Interventions:
1. Pirfenidone 2403 mg/day, n = 174 Length of follow-up: 72 weeks from the
date thelast patient was enrolled
2. Pirfenidone 1197 mg/day, n = 87
Loveman et al. BMC Pharmacology and Toxicology 2014, 15:63 Page 6 of 13
http://www.biomedcentral.com/2050-6511/15/63
Table 1 Study characteristics of included interventions (Continued)
3. Placebo, n = 174
Duration of treatment: 72 weeks
Taniguchi et al., 2010 [16] Mean Age: 65 years Primary outcomes: change in vital capacity
to week 52
Unclear risk
Country: Japan M/F%: 78/22
Design: RCT Time since diagnosis: <1
Number of centres: 73 year: 37% Secondary outcomes: Progression-free
survival time, change in lowest SpO2
during the 6MET. Pa,O2, PA-a,O2, TLC
and DLCO, acute exacerbation, markers
of interstitial pneumonias, symptoms.
Funding: public sector grants. Drug and placebo
from Shionogi & Co, Ltd.
FVC: 78%
1. Pirfenidone 1800 mg/day, n = 108
2. Pirfenidone 1200 mg/day, n = 55
3. Placebo, n = 104 Length of follow-up: 52 weeks
Duration of treatment: 52 weeks
Azuma et al., 2005 [17] Mean Age: 64 years Primary outcomes: change in the lowest
SpO2 during the 6MET
Unclear risk
Country: Japan M/F%: 90/10
Design: RCT Time since diagnosis: <1
Number of centres: 25 year: 22% Secondary outcomes: resting PFTs while
breathing air (VC, TLC, DLCO PaO2),
disease progression by HRCT patterns,
acute exacerbation, serum markers of
pneumocyte damage, QoL
Funding: Shionogi & co, Ltd FVC: 80%
Interventions:
1.Pirfenidone 1800 mg/day, n = 73
2. Placebo, n = 36
Duration of treatment: 9 months
Length of follow-up: minimum of 9 months
Thalidomide
Horton et al., 2012 [24] Mean Age: 68 years Primary outcomes: cough-specific quality
of life (CQLQ)
Low risk
Country: USA M/F%: 78/22
Design: randomised cross-over trial Time since diagnosis: 1.7
Number of centres: one years Secondary outcomes: cough, respiratory
quality of life.
Funding: Celgene Corporation FVC: 70%
Interventions:
1. Thalidomide, n = 23 Method of assessing outcome: Cough-specific
quality of life measured by CQLQ. Cough
measured by 10 cm VAS. Respiratory quality
of life measured by SGRQ.
2. Placebo, n = 23
Duration of treatment: 12 weeks each treatment with a
2 week washout period between treatments.
Length of follow-up: 12 weeks.
Sildenafil (severe IPF)
Zisman and colleagues IPFCRN, 2010 [23] Mean Age: 69 years Primary outcomes: presence or absence
of an improvement of at least 20% in the
6MWT distance at 12 weeks.
Unclear risk
Country: USA M/F%: 84/16
Design: RCT Time since diagnosis: 1.9
Number of centres: 14 years
Funding: NHLBI; the Cowlin Fund (Chicago Community trust);
Pfizer; Masimo.
FVC: 57% Secondary outcomes: changes in the 6MWT
distance, degree of dyspnoea, quality of life,
FVC, DLCO, arterial partial pressure of oxygen
and arterial oxygen saturation, and the
alveolar-arterial oxygen gradient while
breathing ambient air, adverse events,
hospitalisations, death.
1. Sildenafil, n = 89
2. Placebo, n = 91
Duration of treatment: 12 weeks.
Length of follow-up: 12 weeks
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Non-pharmacological interventions
Disease management programme/Pulmonary Rehabilitation
Lindell et al. 2010 [26] Mean Age: 66 years Primary outcomes: Not specified as primary
or secondary outcomes. Dyspnoea (UCSDSBQ);
Anxiety (BAI); Depression (BDI-II); Stress (PSS);
QoL (SF-36)
Unclear risk
Country: USA M/F%: 76/24
Design: RCT Time since diagnosis: NR
Number of centres: one FVC: >55: 70%
Funding: Fairbanks-Horix Foundation
Interventions: Length of follow-up: Unclear
1. Program to Reduce IPF Symptoms and Improve
Management (PRISIM), n = 10 pairs
2. Usual care, n = 11 pairs
Duration of treatment: 6 weeks
Jastrzebski et al. 2008 [27] Mean Age: 56 years Primary outcomes: not specified as primary
or secondary. Dyspnoea (oxygen cost diagram,
baseline dyspnoea index). QoL (SF-36), 6MWT
(distance, dyspnoea in Borg’s scale), maximal
inspiratory pressure, lung function tests
(IC, TLC, VC, FEV1, DLCOSB, DLCO/VA).
High risk
Country: Poland M/F%: 64/36
Design: CCT Time since diagnosis: >2
Number of centres: one years
Funding: not translated FVC: 68%
Interventions:
1. Inspiratory muscle training, n = 16
2. Control, n = 14 Length of follow-up: 12 weeks
Duration of treatment: 12 weeks (two six week cycles)
Nishiyama et al. 2008 [25] Mean Age: 66 years Primary outcomes: not specified as
primary or secondary. Pulmonary
function tests (FVC, FEV1, TLC, PaO2,PaCO2,)
DLCO, 6MWT; BDI; SGRQ
Unclear risk
Country: Japan M/F%: 76/24
Design: RCT Time since diagnosis: NR
Number of centres: one FVC: 67%
Funding: Japanese ministry of health, labor and welfare Length of follow-up: 10 weeks after the start
of the programme.
Interventions:
1. Pulmonary rehabilitation programme (PRP),
n = 15 (13 analysed)
2. Control, n = 15
Duration of treatment: 10 week programme.
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were favourable to pulmonary rehabilitation but not others.
The risk of bias was uncertain and endpoints were only
assessed immediately after the interventions finished. Lim-
ited evidence of the effectiveness of a disease management
programme was demonstrated. This study had an uncertain
risk of bias and follow-up was immediate.
Cost effectiveness and HRQoL systematic reviews
One economic evaluation was identified, which examined
a testing strategy prior to treatment with triple therapy
but did not examine the cost-effectiveness of treatment.
The systematic review of HRQoL included 23 studies that
examined HRQoL using either a generic preference-based
tool (EuroQol five dimensions [EQ-5D], Short Form-36
[SF-36]) or a disease specific instrument (SGRQ) thatcould be mapped to utility for the economic model. Re-
sults varied between the studies, given the different popu-
lations under study and the different measures and time
points of measurement, however, results generally showed
that IPF has an adverse effect on HRQoL which increases
with severity.
Cost-effectiveness of pharmacological treatments for IPF
The baseline risk of disease progression in the unpro-
gressed state was taken from two of the pirfenidone trials
included in the systematic review of clinical effectiveness
[15] as the population most closely met the model defin-
ition of unprogressed IPF and the RCTs had large sample
sizes. The probabilities of progression free survival were
obtained from the Kaplan Meier survival curve published
for the pooled placebo population of two RCTs [15].
Figure 2 Evidence network for FVC endpoint. Legend: The width
of the lines connecting treatment pairs is proportional to the
number of participants within each trial comparison.
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Stata using maximum likelihood estimation in order to ex-
trapolate beyond the 72 weeks follow-up. Exponential,
Weibull, loglogistic, lognormal and Gompertz parametric
models were examined. Goodness of fit was assessed using
the Akaike Information Criterion (AIC). The Weibull
model was selected because of the balance of good fit
(AIC) and face validity (comparison of predicted survival
with known survival in IPF). In the progressed state the
monthly probability of death was taken from the overall
survival curve in a recent study reporting survival for
those experiencing a 10% or greater decline in FVC [30].Table 2 NMA Fixed effects results, SMDs converted to log odd
Comparator (vs. placebo) N studies Total N participants
Azathioprine 1 19
Nintedanib 1 170
NAC triple therapy 2 294




Nintedanib vs. Pirfenidone −0.58This study was an observational study but followed a larger
sample than other published studies that differentiate sur-
vival by FVC decline and was deemed the most appropri-
ate for the evaluation. Five parametric survival curves were
fitted using the distributions noted above. The exponential
distribution was selected (using AIC and face validity) to
extrapolate beyond the five years of observed data.Prob-
abilities of acute exacerbations in both unprogressed and
progressed health states, and probabilities of lung trans-
plant and survival from lung transplant, were taken from
published sources.
HRQoL utility values were applied to each of the alive
health states. These were not differentiated by treatment;
the impact of treatment on utility was assumed to occur
because of delay to disease progression which the model
accounts for. The HRQoL values used for the unpro-
gressed and progressed IPF health states were taken from
EQ-5D values reported in two trials included in the
systematic reviews of clinical effectiveness and HRQoL
[21,24]. These trials were conducted by the same clinical
network and it is likely that the estimates of EQ-5D are
consistent and can therefore be contrasted in our eco-
nomic model. The utility values applied in the model can
be seen in Table 3. Utility associated with lung transplant
is taken from a UK-based study [31] which assessed
HRQoL using the EQ-5D. We weighted the utility to ac-
count for a greater proportion of single lung transplants in
the IPF population than the proportion seen in the study,
based on clinical opinion. Utility data for acute exacerba-
tions were not identified in the literature and therefore a
utility decrement was applied that was in line with decre-
ments seen in those with asthma and chronic obstructive
pulmonary disease (Table 3). Sensitivity analyses were used
to test these utility decrements.
Five types of cost are considered in the economic model.
The costs associated with each treatment were made up of
the costs of the drug and the monitoring costs associated
with the treatment. Dose information and unit costs were
taken from published sources where available [32,33]. Units ratios for slowing the decline in FVC
Log odds ratios Odds ratios
Mean 95% CrI Mean 95% CrI
0.44 −0.30 1.19 1.56 0.74 3.29
−0.97 −1.52 −0.41 0.38 0.22 0.66
−0.06 −0.60 0.48 0.94 0.55 1.62
−0.42 −1.24 0.40 0.66 0.29 1.49
−0.39 −0.62 −0.16 0.68 0.54 0.85
−0.12 −0.65 0.41 0.89 0.52 1.51
−1.18 0.03 0.56 0.31 1.03
Table 3 EQ-5D utility values by model health state
Model health state EQ-5D (SD)
Unprogressed IPF (corresponds with an FVC ~72%) 0.80 (0.20)
Progressed IPF (corresponds with an FVC ~59%) 0.74 (0.19)
Lung transplant
0-6 months after transplant 0.71 (0.38)
7-18 months after transplant 0.72 (0.31)
19-36 months after transplant 0.70 (0.33)
>36 months after transplant 0.68 (0.38)
Acute exacerbation decrement 0.20 (not available)







ICER vs. next best
option (£/QALY)
BSC 3,084 2.98 - -
Azathioprine
& prednisolone
4,313 2.66 Dominated Dominated
NAC triple
therapy
5,021 3.03 41,811 Extended
Dominance
Inhaled NAC 5,029 3.37 5,037 5,037
Sildenafil 12,008 3.11 68,116 Dominated
Pirfenidone 70,118 3.34 190,146 Dominated
Nintedanib 139,613 4.01 132,658 209,246
NB: Nintedanib uses an assumed cost.
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and an assumed cost was used which was also subject to
full sensitivity analysis. Hospital admission costs arising
from acute exacerbations were estimated from NHS refer-
ence costs for all treatments as no treatment-specific acute
exacerbation costs were available (£1361.04) [34]. Ongoing
non-pharmacological treatment costs for management of
the condition were included and covered annual home
oxygen costs (£824.30) and the costs of long-term oxygen
monitoring (£173.94) for the progressed IPF state. The
costs associated with lung transplant were calculated using
NHS reference costs [34] excluding outpatient procedures
(£35,468.61). Costs of adverse events were attributed to the
pharmacological interventions. Based on the incidence of
serious adverse events seen in the trials included in the sys-
tematic review of clinical effectiveness, costs were applied
for each event per patient in the first cycle of the model [34].
The model base-case results show increased survival
for five of the treatments compared with BSC, at in-
creased cost (see Table 4). The combination of azathio-
prine and prednisolone is dominated by BSC (treatment
is more costly and less effective than BSC). Triple ther-
apy is associated with an ICER of £41,811 per QALY
gained when compared to BSC. Inhaled NAC is associ-
ated with an ICER of £5,037 per QALY gained when
compared to BSC. Sildenafil, pirfenidone and nintedanib
are not cost-effective at a willingness to pay (WTP)
threshold of £30,000/QALY when compared to BSC.
Therefore only one treatment, inhaled NAC, is cost-
effective at a £30,000 WTP threshold, but its treatment
effect is not statistically significant in the RCT, a small
study with undetermined risk of bias.
Deterministic and probabilistic sensitivity analyses
tested uncertainty in model parameter values, including
costs and probabilities of acute exacerbation and lung
transplant. Treatment effects and utilities were also varied
in sensitivity analyses. The parameters were varied between
the 2.5th and 97.5th percentiles of the mean value and
analyses found that results were generally robust but
were particularly sensitive to changes in the value of the
treatment effect parameters.The monthly cost of nintedanib was assumed (£3,274).
Results demonstrate that, given a WTP of £30,000 per
QALY, nintedanib must cost less than £736 per month
to be considered as the cost-effective treatment option
compared to BSC and pirfenidone.
Discussion
We systematically reviewed evidence for the clinical effect-
iveness of six pharmacological interventions and two non-
pharmacological interventions for IPF. Participants in most
of these studies would likely be classed as having mild-to-
moderate IPF and generally were similar to those seen in
clinical practice. There was a range of treatments under in-
vestigation in these trials with only one treatment, pirfeni-
done, providing evidence from more than one trial that
was suitable for a formal meta-analysis to be undertaken.
The outcomes reported in these studies differed however,
and therefore caution is required when considering the
results of the meta-analysis and the narrative synthesis of
each of the included studies. In a network meta-analysis of
the pharmacological treatments only pirfenidone and nin-
tedanib had a statistically significant treatment effect, redu-
cing the rate of decline in FVC compared to placebo. One
pharmacological treatment was excluded from the network
meta-analysis as the focus of treatment was not on lung
function but on the symptom cough. In this study thalido-
mide appeared to improve cough, and quality of life com-
pared with a placebo treatment. Results of three studies
investigating two non-pharmacological treatments show
mixed results and it is therefore unclear how effective these
interventions are. There are differences between the stud-
ies in terms of the interventions, the participants, and the
outcomes reported together with study design issues
(e.g. short follow-up) and uncertain risk of bias that may
account for some of the results seen.
Evidence from systematic reviews of cost effectiveness
and HRQoL identified one economic evaluation of limited
relevance and 23 HRQoL studies. These latter studies var-
ied in their populations and study methods but generally
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pared to population norms, and that HRQoL diminishes as
IPF progresses. A new decision analytic health economic
model was developed to assess the cost-effectiveness of six
pharmacological treatments for IPF. Results show in-
creased survival for five of the treatments compared with
best supportive care, at increased cost. Only one treatment,
inhaled NAC, is cost-effective at a WTP threshold of
£30,000 but no statistically significant treatment effect was
seen in the RCT or our NMA. Probabilistic sensitivity
analysis showed that inhaled NAC has a 65% probability of
being cost-effective if a decision threshold of £20,000 per
QALY gained is used. Although pirfenidone and nintedanib
achieve a statistically significant treatment effect in NMA
they each have a probability of 0% of being cost-effective at
a threshold of £30,000 per QALY. This is based on an as-
sumed cost for nintedanib. A sensitivity analysis indicated
that nintedanib must cost less than £736 per month to be
considered cost-effective.
The past few years have seen an increasing interest in
the management of IPF, with pharmacological companies
evaluating a range of potential interventions, and a num-
ber of influential bodies producing guidelines. However,
this systematic review demonstrates that at present there
are few treatments which have any effect on surrogate
outcomes which can be linked through evidence to patient
related outcomes such as mortality. The findings of our
research also suggest that under current willingness to pay
thresholds only one treatment is likely to be cost effective,
although, general recommendations cannot be made due
to limitations in the evidence base. In terms of a cure it is
considered that lung transplantation is the only interven-
tion available which has curative intent. However, no evi-
dence on lung transplant was eligible for inclusion in this
evidence synthesis and so this could not be evaluated for-
mally. There is also a scarcity of studies on interventions
for symptom management and palliative care in IPF des-
pite this being a recommended approach in recent clinical
guidance [5].
No previous systematic reviews have included all poten-
tially relevant treatments for IPF, and there has only been
limited economic evaluation previously. Our results are
useful to clinicians and patients, and complement recent
national guidance by NICE in the UK [5]. In addition to
standard synthesis we undertook a network meta-analysis
to compare the pharmacological therapies to a common
comparator. Our results show that only two treatments
(nintedanib and pirfenidone) significantly slow the decline
in FVC compared to placebo under a fixed effect model.
However, with few studies it was not possible to fully
explore heterogeneity within these data and the results
should be cautiously interpreted. We also undertook an il-
lustrative analysis comparing nintedanib with pirfenidone
through an indirect comparison. While this showed atrend favouring nintedanib, it was not statistically signifi-
cant and should be interpreted with caution until such
time that a more complete analysis can be undertaken on
more robust data. We identified a number of ongoing
trials of potential relevance. Our evidence synthesis has
highlighted the current evidence base in which these new
trials can be contextualised once they report.
There were numerous differences between the studies
included in this review. However we applied a rigorous
approach to the inclusion, quality assessment and data
synthesis of the studies (laid out in a research protocol),
to ensure that our work was as unbiased as possible.
Our research was guided by an advisory group from its
initiation, in particular to ensure that the interventions in-
cluded were appropriate to current or future management
in the NHS. We ensured that only the highest quality
studies were included to limit uncertainty in the results.
Our study has several limitations. The meta-analysis
and NMA used the standardised mean difference to ex-
press findings from studies on a common scale. In this
case we combined mean change in FVC% predicted with
absolute change in FVC, albeit the former is adjusted for
certain baseline characteristics, and this should be
considered when interpreting the results. Many of the
included studies compared treatments to placebo. Few
direct comparisons were identified and results of an in-
direct comparison via the NMA approach are presented.
However there are known limitations to the use of indir-
ect comparisons which should also be considered in
interpreting our findings [35]. The economic model as-
sumes that treatments have a constant effect on the relative
rate of FVC% decline compared to BSC, but treatment may
in fact become less effective with time or as the condition
progresses. (This would make the treatments less cost-
effective than shown in our results.) Finally, because of
limitations in the data the absolute decline in FVC% pre-
dicted was used as the measure of disease progression in
the model. It is possible that use of this measure may intro-
duce bias because the starting FVCs of patients (which
might vary widely) is not taken into account.
Conclusions
This evidence synthesis reports on the effectiveness of a
range of interventions for IPF and complements recent
UK guidance [5]. The current evidence suggests that there
are currently few treatments which are clinically and cost-
effective. Pirfenidone and nintedanib offer the potential
for hope to sufferers and their clinicians, however, their
cost-effectiveness is likely to be prohibitive. This research
has thoroughly examined the current evidence and can be
seen as a platform from which the clinical importance of
newer treatments can be assessed when ongoing trials
report. The systematic review has highlighted the need for
further research into interventions to help alleviate or
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lar pulmonary rehabilitation programmes and thalido-
mide. Given the results of our study and the weaknesses
of the inhaled NAC trial, a well-designed RCT of inhaled
NAC should also be considered; our search of ongoing
RCTs failed to identify any such studies currently underway.
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